title: A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom.
abstract: BACKGROUND
  Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk. The study assesses the cost-effectiveness of palivizumab versus no prophylaxis in infants at high risk of hospitalisation with RSV in the United Kingdom (UK).
  
  
  METHODS
  A decision tree model was developed to reflect the clinical pathway of infants at high risk of severe RSV infection who receive either prophylaxis with palivizumab or no prophylaxis. The main outcome was the incremental cost-effectiveness ratio (ICER). One-way and probabilistic sensitivity analyses were performed to assess the degree of uncertainty surrounding the results. A threshold analysis considered the impact of clinical and environmental risk factors on the cost-effectiveness in the subgroup of preterm infants 33-35 weeks gestational age (wGA).
  
  
  RESULTS
  Prophylaxis with palivizumab compared with no prophylaxis is associated with the following ICERs; £33,216 for infants with congenital heart disease; £19,168 for infants with chronic lung disease; £3,845 for preterm infants < 29 wGA; £30,205 for preterm infants 29-32 wGA; and £99,056 for preterm infants 33-35 wGA. One-way sensitivity analysis suggests that these results are highly sensitive to the input data. Threshold analysis in the preterm 33-35 wGA subgroup demonstrates that an adjusted RSV-hospitalisation baseline risk of 17.94% or higher would result in an ICER below the £30,000 per quality-adjusted life-year threshold.
  
  
  CONCLUSIONS
  Palivizumab is cost-effective compared to no prophylaxis in the United Kingdom in many of the subgroups considered, showing that palivizumab would be a cost-effective use of National Health Service resources.
authors.affiliation: Health Economics, Abacus International, 6 Talisman Business Centre, Talisman Road, Bicester, Oxfordshire OX26 6HR, UK. Anthony.Bentley@abacusint.com.
authors.forename: Anthony
authors.initials: A
authors.lastname: Bentley
authors.forename: Ivana
authors.initials: I
authors.lastname: Filipovic
authors.forename: Katherine
authors.initials: K
authors.lastname: Gooch
authors.forename: Katharina
authors.initials: K
authors.lastname: Büsch
references.citation: Health Technol Assess. 2011 Jan;15(5):iii-iv, 1-124
references.pmid: 21281564
references.citation: Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S76-82
references.pmid: 12671456
references.citation: Arch Dis Child. 2001 Dec;85(6):463-8
references.pmid: 11719328
references.citation: Epidemiol Infect. 2002 Aug;129(1):99-106
references.pmid: 12211603
references.citation: Pharmacoeconomics. 2007;25(1):55-71
references.pmid: 17192118
references.citation: Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86
references.pmid: 19049692
references.citation: N Engl J Med. 2009 Feb 5;360(6):588-98
references.pmid: 19196675
references.citation: J Clin Virol. 2011 Nov;52(3):215-21
references.pmid: 21880543
references.citation: Pediatrics. 1998 Sep;102(3):531-7
references.pmid: 9724660
references.citation: J Pediatr. 2003 Oct;143(4):532-40
references.pmid: 14571236
references.citation: Curr Top Microbiol Immunol. 2008;317:103-23
references.pmid: 17990791
references.citation: Arch Dis Child. 2003 Dec;88(12):1065-9
references.pmid: 14670770
references.citation: Pediatr Infect Dis J. 2003 Feb;22(2 Suppl):S58-64; discussion S64-5
references.pmid: 12671454
references.citation: Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S193-201
references.pmid: 15577573
references.citation: Pediatr Infect Dis J. 2000 Jul;19(7):592-7
references.pmid: 10917214
references.citation: Eur J Pediatr. 2012 Jul;171(7):1055-61
references.pmid: 22302458
references.citation: Heart. 2001 Apr;85(4):438-43
references.pmid: 11250973
references.citation: Pediatr Infect Dis J. 2006 Mar;25(3):201-7
references.pmid: 16511380
references.citation: Pediatrics. 2004 Dec;114(6):1606-11
references.pmid: 15574622
references.citation: Arch Dis Child. 2004 Jul;89(7):673-8
references.pmid: 15210503
references.citation: Acta Paediatr. 2011 Oct;100(10):1302-5
references.pmid: 21781158
references.citation: Med Decis Making. 2008 Jul-Aug;28(4):471-80
references.pmid: 18556643